08:09 AM EDT, 10/08/2025 (MT Newswires) -- CervoMed ( CRVO ) said Wednesday that new data from its mid-stage trial showed that its drug, neflamapimod, may be a potential treatment for dementia with Lewy bodies, particularly in patients without signs of Alzheimer's disease co-pathology.

The company said the results are from the final analysis of the 48-week trial, which included a 16-week placebo-controlled phase followed by a 32-week extension where all participants received neflamapimod.

During the extension phase, the company said the participants who received an updated version of the drug, one that reached the desired blood levels, showed significant improvement in cognitive and functional measures when compared to those who continued on the previous batch or switched from placebo.

The patients also experienced slower disease progression, improved memory and daily functioning scores, and a meaningful clinical benefit, the company added.

In addition to clinical outcomes, the company said neflamapimod also reduced levels of GFAP, a blood biomarker associated with neurodegeneration.

The company said it expects the US Food and Drug Administration's feedback on the late-stage design in Q4.

Shares of the company were up 16% in recent Wednesday premarket activity.